drugset
drugset / Trial / NCT05736887

Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19

NCT05736887 ↗

Phase 2 Unknown 80 enrolled Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized, double-blind, parallel-arm, phase II, explorative study investigating the efficacy and safety of orally administered N-Acetylcysteine (NAC) versus placebo in patients with history of SARS-Cov-2 infection and residual respiratory impairment.

Timeline

Start
2022-05-24
Primary completion
2023-01-16
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg Oral

Indications

COVID-19